@article { ISI:000268335600001,
	title = {Challenges associated with metal chelation therapy in alzheimer{\textquoteright}s disease},
	journal = {Journal of Alzheimers Disease},
	volume = {17},
	number = {3},
	year = {2009},
	month = {JUL},
	pages = {457-468},
	publisher = {IOS PRESS},
	address = {NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS},
	abstract = {<p>A close association between brain metal dishomeostasis and the onset and/or progression of Alzheimer{\textquoteright}s disease ( AD) has been clearly established in a number of studies, although the underlying biochemical mechanisms remain obscure. This observation renders chelation therapy an attractive pharmacological option for the treatment of this disease. However, a number of requirements must be fulfilled in order to adapt chelation therapy to AD so that the term {\textquoteleft}{\textquoteleft}metal targeted strategies{\textquoteright}{\textquoteright} seems now more appropriate. Indeed, brain metal redistribution rather than brain metal scavenging and removal is the major goal of this type of intervention. The most recent developments in metal targeted strategies for AD will be discussed using, as useful examples, clioquinol, curcumin, and epigallocatechin, and the future perspectives will also be outlined.</p>},
	keywords = {Alzheimer{\textquoteright}s disease, clioquinol, cuprizone, metal dishomeostasis, metal ions, nanomedicine, Parkinson{\textquoteright}s disease, polyphenols},
	issn = {1387-2877},
	doi = {10.3233/JAD-2009-1068},
	author = {Hegde, Muralidhar L. and Bharathi, P. and Suram, Anitha and Venugopal, Chitra and Jagannathan, Ramya and Poddar, Pankaj and Srinivas, Pullabhatla and Sambamurti, Kumar and Rao, Kosagisharaf Jagannatha and Scancar, Janez and Messori, Luigi and Zecca, Luigi and Zatta, Paolo}
}
